CORDIS
EU research results

CORDIS

English EN
Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise

Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise

Objective

Type 1 diabetes is caused by an inflammatory process which damage insulin-producing beta-cells in the pancreas. It is one of the most common chronic diseases and its incidence is rapidly increasing. Due to its complications it causes a significant medical and economic burden to European society. A causal association between enterovirus and type 1 diabetes has become more and more likely. The aim of the present research programme is to create a new research strategy aligned to a concerted scientific research effort and creation of a network of unique resources which makes it possible to achieve a significant breakthrough in this field. The main focus is in the detection of persistent enterovirus infection leading to inflammation and tissue damage in the pancreas and its role in mediating the inflammatory response that causes type 1 diabetes. The goal is to take the critical steps towards therapeutic translation of research findings by employing a novel research design and synergistic networks of excellence based on the combination of a multidisciplinary research strategy and availability of unique biobanks existing in Europe. This research programme will also create a completely new type of biobank which facilitates a wide range of new analyses of fresh tissues. The programme includes a strong translational component which facilitates the ongoing efforts to develop vaccines against diabetogenic enteroviruses and other targeted therapies. The program also has a wider impact on the entire field of research on pathogen-disease associations, since the same innovative research strategy can be applied to other diseases as well. Altogether, this research program will take full advantage of the excellent biobank networks and a long tradition in biomedical and clinical research in Europe and creates an exceptional opportunity to take the final steps towards proving causality in the enterovirus-diabetes association.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

TAMPEREEN YLIOPISTO

Address

Kalevantie 4
33014 Tampere

Finland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 820 760

Administrative Contact

Susanna Airila (Ms.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 1 242 918

UNIVERSITA DEGLI STUDI DI SIENA

Italy

EU Contribution

€ 493 000

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 459 000

THE UNIVERSITY OF EXETER

United Kingdom

EU Contribution

€ 346 434

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 340 000

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 349 764

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

France

EU Contribution

€ 348 000

TURUN YLIOPISTO

Finland

EU Contribution

€ 477 000

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 260 011

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 362 400

VACTECH OY

Finland

EU Contribution

€ 247 200

DIAMYD THERAPEUTICS AB

Sweden

EU Contribution

€ 133 200

LINKOPINGS UNIVERSITET

Sweden

EU Contribution

€ 120 000

Project information

Grant agreement ID: 261441

Status

Closed project

  • Start date

    1 January 2011

  • End date

    30 June 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 901 998,40

  • EU contribution

    € 5 999 687

Coordinated by:

TAMPEREEN YLIOPISTO

Finland